The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety

PHASE1CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

April 26, 2021

Study Completion Date

May 25, 2021

Conditions

Asthma

Interventions

DRUG

Omalizumab

Biological: CMAB007 Biological: Xolair

Trial Locations (1)

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors

lead

Taizhou Mabtech Pharmaceutical Co.,Ltd

INDUSTRY

NCT04778137 - The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety | Biotech Hunter | Biotech Hunter